Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DDX60

Gene summary for DDX60

Gene summary.

Gene information	Species	Human
	Gene symbol	DDX60
	Gene ID	55601
	Gene name	DExD/H-box helicase 60
	Gene Alias	DDX60
	Cytomap	4q32.3
	Gene Type	protein-coding
	GO ID	GO:0002221
	UniProtAcc	Q6B0F7

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55601	DDX60	LZE5T	Human	Esophagus	ESCC	1.95e-02	2.61e-01	0.0514
55601	DDX60	LZE8T	Human	Esophagus	ESCC	2.74e-04	1.37e-01	0.067
55601	DDX60	LZE20T	Human	Esophagus	ESCC	9.67e-07	1.67e-01	0.0662
55601	DDX60	LZE24T	Human	Esophagus	ESCC	1.73e-15	5.58e-01	0.0596
55601	DDX60	P1T-E	Human	Esophagus	ESCC	3.60e-06	2.58e-01	0.0875
55601	DDX60	P2T-E	Human	Esophagus	ESCC	9.23e-48	8.57e-01	0.1177
55601	DDX60	P4T-E	Human	Esophagus	ESCC	6.03e-05	8.93e-02	0.1323
55601	DDX60	P5T-E	Human	Esophagus	ESCC	6.03e-08	1.97e-01	0.1327
55601	DDX60	P8T-E	Human	Esophagus	ESCC	1.40e-12	3.02e-01	0.0889
55601	DDX60	P9T-E	Human	Esophagus	ESCC	5.04e-15	1.50e-01	0.1131
55601	DDX60	P11T-E	Human	Esophagus	ESCC	6.89e-10	4.83e-01	0.1426
55601	DDX60	P12T-E	Human	Esophagus	ESCC	6.61e-09	2.34e-01	0.1122
55601	DDX60	P15T-E	Human	Esophagus	ESCC	4.90e-08	3.47e-01	0.1149
55601	DDX60	P17T-E	Human	Esophagus	ESCC	1.88e-08	4.10e-01	0.1278
55601	DDX60	P20T-E	Human	Esophagus	ESCC	5.53e-12	3.44e-01	0.1124
55601	DDX60	P21T-E	Human	Esophagus	ESCC	2.71e-14	4.34e-01	0.1617
55601	DDX60	P22T-E	Human	Esophagus	ESCC	1.89e-09	1.04e-01	0.1236
55601	DDX60	P23T-E	Human	Esophagus	ESCC	1.13e-04	1.95e-01	0.108
55601	DDX60	P24T-E	Human	Esophagus	ESCC	4.51e-21	5.26e-01	0.1287
55601	DDX60	P26T-E	Human	Esophagus	ESCC	9.22e-10	2.75e-01	0.1276

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0039531	Liver	HCC	regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway	20/7958	24/18723	4.92e-05	4.70e-04	20
GO:00028312	Liver	HCC	regulation of response to biotic stimulus	173/7958	327/18723	8.55e-05	7.48e-04	173
GO:00395351	Liver	HCC	regulation of RIG-I signaling pathway	17/7958	20/18723	1.18e-04	9.87e-04	17
GO:00622072	Liver	HCC	regulation of pattern recognition receptor signaling pathway	59/7958	105/18723	3.18e-03	1.47e-02	59
GO:0039530	Liver	HCC	MDA-5 signaling pathway	9/7958	11/18723	9.51e-03	3.60e-02	9
GO:000961515	Oral cavity	OSCC	response to virus	215/7305	367/18723	1.63e-14	9.41e-13	215
GO:00516074	Oral cavity	OSCC	defense response to virus	154/7305	265/18723	1.96e-10	5.63e-09	154
GO:01405464	Oral cavity	OSCC	defense response to symbiont	154/7305	265/18723	1.96e-10	5.63e-09	154
GO:003052218	Oral cavity	OSCC	intracellular receptor signaling pathway	149/7305	265/18723	8.69e-09	1.81e-07	149
GO:00028317	Oral cavity	OSCC	regulation of response to biotic stimulus	177/7305	327/18723	1.73e-08	3.43e-07	177
GO:00022214	Oral cavity	OSCC	pattern recognition receptor signaling pathway	95/7305	172/18723	1.11e-05	1.15e-04	95
GO:00027537	Oral cavity	OSCC	cytoplasmic pattern recognition receptor signaling pathway	40/7305	60/18723	1.32e-05	1.33e-04	40
GO:00321037	Oral cavity	OSCC	positive regulation of response to external stimulus	203/7305	427/18723	1.79e-04	1.22e-03	203
GO:00395283	Oral cavity	OSCC	cytoplasmic pattern recognition receptor signaling pathway in response to virus	24/7305	34/18723	1.89e-04	1.28e-03	24
GO:00395301	Oral cavity	OSCC	MDA-5 signaling pathway	10/7305	11/18723	5.78e-04	3.30e-03	10
GO:00985866	Oral cavity	OSCC	cellular response to virus	47/7305	84/18723	1.20e-03	6.06e-03	47
GO:00622076	Oral cavity	OSCC	regulation of pattern recognition receptor signaling pathway	56/7305	105/18723	1.99e-03	9.23e-03	56
GO:00027646	Oral cavity	OSCC	immune response-regulating signaling pathway	212/7305	468/18723	2.93e-03	1.27e-02	212
GO:00395294	Oral cavity	OSCC	RIG-I signaling pathway	18/7305	27/18723	3.34e-03	1.42e-02	18
GO:00622087	Oral cavity	OSCC	positive regulation of pattern recognition receptor signaling pathway	26/7305	44/18723	5.49e-03	2.13e-02	26

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DDX60

SNV

Missense_Mutation

novel

c.1426G>T

p.Asp476Tyr

p.D476Y

Q8IY21

protein_coding

deleterious(0.01)

probably_damaging(0.962)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DDX60

SNV

Missense_Mutation

novel

c.4583N>T

p.Tyr1528Phe

p.Y1528F

Q8IY21

protein_coding

deleterious(0.01)

possibly_damaging(0.886)

TCGA-AR-A0TU-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Doxorubicin

DDX60

SNV

Missense_Mutation

novel

c.2341N>A

p.Ala781Thr

p.A781T

Q8IY21

protein_coding

deleterious(0)

probably_damaging(0.981)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

DDX60

SNV

Missense_Mutation

c.2306N>A

p.Arg769Gln

p.R769Q

Q8IY21

protein_coding

deleterious(0.04)

possibly_damaging(0.463)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

DDX60

SNV

Missense_Mutation

c.1613N>C

p.Phe538Ser

p.F538S

Q8IY21

protein_coding

deleterious(0)

possibly_damaging(0.839)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

DDX60

SNV

Missense_Mutation

c.1528N>C

p.Asp510His

p.D510H

Q8IY21

protein_coding

deleterious(0)

probably_damaging(0.973)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

DDX60

SNV

Missense_Mutation

c.3790C>T

p.His1264Tyr

p.H1264Y

Q8IY21

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DDX60

SNV

Missense_Mutation

c.1780N>A

p.Glu594Lys

p.E594K

Q8IY21

protein_coding

tolerated(0.12)

benign(0.043)

TCGA-D8-A73U-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

DDX60

SNV

Missense_Mutation

c.3231N>C

p.Lys1077Asn

p.K1077N

Q8IY21

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-E2-A10C-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

DDX60

SNV

Missense_Mutation

novel

c.362N>G

p.Thr121Arg

p.T121R

Q8IY21

protein_coding

deleterious(0)

probably_damaging(0.979)

TCGA-E2-A574-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1